AK

Ashwani Kumar

Director Director DIN 09811823
DIN 09811823 First appointment Nov 2022 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Nov 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Ashwani Kumar

Data last updated:

Ashwani Kumar was a Director at Oscar Remedies Pvt Ltd (2022–2024) and Director at Oscar Bioscience Private Limited (2024). The companies operate in Pharma and Paper.

DIN 09811823
Primary Designation Director
Industry Pharma
First Appointment 29 Nov 2022

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Oscar Remedies Pvt Ltd U24230HR1990PTC031079
Director29 Nov 20221990₹82.04 Cr (FY 2025)Active
Oscar Bioscience Private Limited U21004HR2024PTC121068
Director27 Apr 20242024Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Oscar Remedies Pvt Ltd
Oscar Bioscience Private Limited
Premium access

Shareholding and investment profile for Ashwani Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashwani Kumar

Ashwani Kumar was first appointed on 29 Nov 2022 as Director at Oscar Remedies Pvt Ltd. The most recent appointment on record is 27 Apr 2024 at Oscar Bioscience Private Limited.

Ashwani Kumar held 2 earlier board appointments: Oscar Remedies Pvt Ltd (Director, 29 Nov 2022 to 07 Oct 2024); Oscar Bioscience Private Limited (Director, 27 Apr 2024 to 10 Oct 2024).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available